The role of RORα in salivary gland lesions in patients with primary Sjögren’s syndrome

Xiuhong Weng 1, Yi Liu 2, Shun Cui 3* and Bo Cheng 1*

Abstract

Background: The orphan nuclear receptors retinoic acid-related receptor α (RORα) and γ (RORγt) are critical in the development of T helper 17 (Th17) cells, and ROR-specific synthetic ligands have proven efficacy in several mouse models of autoimmunity. However, the pathological significance of RORα in primary Sjögren’s syndrome (pSS) remains to be elucidated. The present study was designed to clarify the significance of RORα in the pathogenesis of pSS.

Methods: RORα expression in the labial salivary gland (LSG) was determined by immunohistochemical analysis using a quantitative scoring system in 34 patients with pSS. The correlation between RORα expression in LSGs and the focus score (FS) was determined, and Th17 and IL-17 receptor A (1L-17RA) levels in LSGs were determined. To investigate the effect of RORs and the therapeutic potential of targeting RORs in pSS, we administered SR1001, a selective RORα/γt inverse agonist, to non-obese diabetic (NOD) mice.

Results: The expression of RORα was significantly increased in LSGs of patients with pSS and intensified with disease stage/FS, showing a similar increasing trend with IL-17A and IL-17RA. SR1001 significantly improved salivary gland secretory function and relieved sialadenitis in treated mice.

Conclusion: Our data reveal the importance of RORα in controlling pathologic lymphocytic infiltration of the salivary glands and suggest that RORα may be a druggable target in treating pSS.

Keywords: Primary Sjögren’s syndrome, RORα, Focus score, Th17 cells, Inverse agonist

Background

Primary Sjögren’s syndrome (pSS) is a chronic, systemic autoimmune disease characterized by lymphocyte infiltration into exocrine glands, such as salivary and lacrimal glands. The main clinical manifestations include xerostomia, xerophthalmia and several systemic manifestations. In addition, the probability of developing lymphoma is significantly higher (up to 44-fold higher) in patients with pSS than in the normal population [1, 2].

Focal lymphocytic sialadenitis is the characteristic histopathological feature of pSS. Minor salivary glands are more likely to have a focus score (FS), which is an index of inflammation, of at least 1 when evaluated by an expert histopathologist [3]. In addition, high concentrations of anti-Ro/La antibodies (SSA/SSB), anti-nuclear antibody (ANA), rheumatoid factor (RF) and immunoglobulin G (IgG) are detected in the plasma of patients with a FS greater than or equal to 1 [4]. Thus, it has been suggested that the FS may be associated with disease activity. The diagnosis of pSS is based on clinical manifestations and laboratory examination [5]. Immunological studies must include a determination of autoantibodies to the SSA and SSB antigens. Minor salivary gland (MSG) biopsy is highly specific for the diagnosis of SS and is indicated principally in patients who are negative for anti-SSA/SSB antibodies.

The pathogenesis of pSS is not yet clear. Immunohistochemical studies have shown that T helper 17 (Th17) cells are among the infiltrating lymphocytes in the labial...
salivary glands (LSGs) and lacrimal glands [6–9]. High levels of interleukin-17 (IL-17) and Th17-related cytokines have recently been identified in the salivary glands and plasma of patients with pSS and in mouse models of pSS [6, 8, 9]. Blocking IL-17 can significantly improve salivary gland function and reduce gland inflammation in pSS animal models [10]. Retinoic acid-related orphan receptors (RORs) are transcription factors that participate in the differentiation of inflammatory Th17 cells and cytokine production [11–15]. RORα cooperates with RORγt and nuclear factor κB inhibitor ζ (IκB) to enhance IL-17 expression by binding directly to the regulatory region of the IL-17A gene [13, 16]. Although several studies have indicated that Th17-related cytokines may be involved in the development of pSS, there is little information on the pathological importance of RORα in pSS. To address this issue, we used the inverse agonist SR1001, which has been found to obstruct Th17 differentiation by specifically inhibiting RORα [11]. This study aimed to investigate the role of RORα in salivary gland inflammation and function in pSS and to explore its role in the progression of pSS, with the goals of providing a theoretical basis and scientific evidence for key targets in the pathogenesis of pSS and improving the clinical diagnosis, staging, and treatment of pSS.

**Methods**

**LSG histology**

LSG biopsy specimens were obtained with informed consent from 34 individuals undergoing diagnostic evaluation for sicca symptoms indicative of pSS and diagnosed by American-European Sjögren’s syndrome (SS) consensus criteria. The control group consisted of 12 gender-matched individuals with subjective complaints of dry mouth or eyes but who did not fulfill the criteria for pSS and had no histopathological evidence of pSS. None of the patients had evidence of lymphoma, sarcoidosis, essential mixed cryoglobulinemia, or HIV or hepatitis B or C virus infection at the time of the study. In addition, patients’ medical records were evaluated for clinical and serological parameters, including SSA and SSB antibodies, high erythrocyte sedimentation rate (ESR), and C3/C4 hypocomplementemia.

The inflammatory lesions were graded histologically (histological FS) using the following method proposed by Greenspan: FS 1, a single focus composed of ~50 mononuclear cells per 4 mm² tissue. Salivary gland histopathology and rank were evaluated by researchers who were blinded to diagnosis, and at least one tissue section from each salivary gland was examined. Biopsy specimens were fixed, embedded, sectioned (4 μm/section), deparaffinized, rehydrated in alcohol, and stained with H&E.

**Immunofluorescence of human samples**

Paraffin sections were placed on silane-coated slides, dewaxed, rehydrated, and heated in citric acid (pH 6.0) buffer for 7 min for antigen retrieval. The sections were incubated with ice-cold blocking solution (PBS containing 5% (vol/vol) donkey serum and 1% (wt/vol) BSA) for 1 h and the primary antibody (RORα, 1:200; Abcam, UK) diluted 1/10 in blocking solution overnight at 4 °C, followed by three washes with Tris-buffered-saline Tween (TBST), and finally incubated with 488 Donkey-Anti-Rabbit IgG (H + L) (1: 400, Jackson Immunoresearch) for 1 h. Nucleus was stained with diamidino-phenyl-indole (DAPI) (Guge, Wuhan). Staining of CD4 (1:100, Biolegend) and IL-17 (1:100, Peprotech) was as herein before. Confocal images were acquired with the same pinhole diameter for each channel.

**Immunohistochemical analysis of human samples**

Paraform sections were placed on silane-coated slides, dewaxed, rehydrated and heated in citric acid (pH 6.0) buffer for antigen retrieval. Endogenous peroxidase activity was blocked with 3% H₂O₂ for 15 min. Then, sections were incubated with blocking serum (ZSGB-BIO, Beijing) for 1 h and then with IL-17RA (1:100, Sangon Biotech, Shanghai) primary antibody overnight at 4 °C. After 20-min incubation with biotinylated secondary antibody (ZSGB-BIO, Beijing), staining was developed for 20 min with an Avidin: Biotinylated Enzyme Complex (ZSGB-BIO, Beijing), followed by 3,3-diaminobenzidine (DAB) staining (ZSGB-BIO, Beijing) and counterstaining with Meyer’s hematoxylin for 1 min. Slides were washed in TBST 3 × 5 minutes after each step. Staining of RORγt (1:50, Abcam) was done as herein before.

**Mice**

Female NOD/LtJ mice, 4 weeks old (4W) and 8 weeks old (8W) were obtained from Huafukang (Beijing) and were maintained in specific pathogen-free conditions at the Animal Experiment Center of Huazhong University of Science and Technology. NOD mice were injected intraperitoneally (i.p.) twice a day with vehicle or SR1001, which was dissolved in a 50% dimethyl sulphoxide (DMSO) and 50% normal saline (dose 2.5 mg/ml, equal to 25 mg/kg and 1 μl/g body weight). Mice were divided into four groups: 4W mice treated i.p. with SR1001 or vehicle; and 8W mice treated i.p. with SR1001 or vehicle. Each group received SR1001 or vehicle i.p. for 4 weeks. Salivary gland function (measurement of saliva flow rate) and blood glucose (Roche, Switzerland) were evaluated before and after the drug intervention. Body weight was measured every day to monitor any effects of SR1001 on growth and development. After 4 weeks, mice were sacrificed, and the isolated salivary glands were H&E stained to observe salivary gland structure. The treatment effect of
SR1001 on salivary gland function was measured by saliva volume secreted in 15 min. Mesenteric lymph nodes (MLNs) and cervical lymph nodes (CLNs) were removed, and the ratio of CD4+/IL-17A+ cells was measured by flow cytometry. All experiments were performed according to the Guide for the Care and Use of Laboratory Animals at Tongji Medical College.

Measurement of stimulated saliva flow
Each NOD mouse was first anesthetized with an i.p. injection of pentobarbital (25 mg/kg/body weight, Sigma-Aldrich, USA) and a subsequent i.p. injection of pilocarpine (1.0 mg/kg/body weight, Leqi, Wuhan). At 1 min after injection of the secretagogue, saliva was collected from the oral cavity using a 200-μl micropipette for 15 min at room temperature. The volume (μl) of each saliva sample was measured and expressed relative to body weight (grams). Baseline saliva flow rates were measured 3 days before the drug injection, and final saliva flow rates in each group were measured the end of the drug injection.

Flow cytometry
Tissue was cut into small pieces for flow cytometric analysis of MLNs and CLNs cells. T cells were cultured for Th17 differentiation as previously described [17]. Staining for CD4 (1:100, BioLegend) expression was performed for 20 min using a mixture of antibodies. Intracellular staining for IL-17A (1:100, BioLegend) was performed after fixation and permeabilization according to the protocol supplied by the manufacturer (BD Biosciences). Samples were analyzed with a FACSCalibar Flow Cytometer (BD Biosciences), and data were analyzed with FlowJo software (Tree Star, Ashland, OR, USA).

Western blot
Minor salivary gland proteins were isolated, and western blotting was performed as follows. Proteins were extracted in the radio-immunoprecipitation (RIPA)-cocktail buffer and centrifuged. The supernatant was collected as the RIPA soluble fraction, and the pellet was washed with RIPA buffer, centrifuged and boiled with Laemmli buffer. The concentration of extracted proteins was measured using a BCA protein assay kit (Byotime, Shanghai). The concentration of extracted proteins was measured using a BCA protein assay kit (Byotime, Shanghai). The concentration of extracted proteins was measured using a BCA protein assay kit (Byotime, Shanghai). The concentration of extracted proteins was measured using a BCA protein assay kit (Byotime, Shanghai). The concentration of extracted proteins was measured using a BCA protein assay kit (Byotime, Shanghai). The concentration of extracted proteins was measured using a BCA protein assay kit (Byotime, Shanghai).

Tissue was cut into small pieces for flow cytometric analysis of MLNs and CLNs cells. T cells were cultured for Th17 differentiation as previously described [17]. Staining for CD4 (1:100, BioLegend) expression was performed for 20 min using a mixture of antibodies. Intracellular staining for IL-17A (1:100, BioLegend) was performed after fixation and permeabilization according to the protocol supplied by the manufacturer (BD Biosciences). Samples were analyzed with a FACSCalibar Flow Cytometer (BD Biosciences), and data were analyzed with FlowJo software (Tree Star, Ashland, OR, USA).

RNA extraction and real-time quantification PCR
Total RNA was obtained from frozen human labial gland specimens from patients with and without pSS using Trizol reagent according to the protocol supplied by the manufacturer (TaKaRa, Japan). Complementary DNA (Cdna) was synthesized from RNA using PrimeScript RT reagent Kit with gDNA Eraser (TaKaRa, Japan). Real-time PCR for H-RORyt and RORytα were performed on StepOne Real-Time (Life Technologies) using the SYBR® Premix Ex Taq kit (TaKaRa, Japan), and H-GAPDH as normalization control. We used the 2-ΔΔCT method for data analysis. Each sample was tested in triplicate, and tests were replicated twice. The primer sets for RT-PCR can be found in Table 1.

Statistical analysis
Data were analyzed by the two-tailed Student's t test using Graphpad Prism. Data are presented as the mean or mean ± SEM. P values are denoted as follows: *P < 0.05, **P < 0.01, ***P < 0.001.

Results
Patients
RORytα expression in LSGs was determined in 46 patients with sicca syndrome who were referred to our department. Thirty-four patients met the American-European Consensus Group criteria for pSS. The remaining 12 patients were classified as having non-SS sicca syndrome. The characteristics of these patients are shown in Table 2. The mean (±SEM) age of the patients with pSS and those with non-pSS was 34.32 ± 2.225 years and 27.25 ± 7.186 years, respectively. All patients were female.

Increased RORytα expression in LSGs of patients with pSS
Typical histologic characteristics of LSGs from patients with pSS were acinus atrophy and local

| Primer set for RT-PCR |
|----------------------|
| Primer sequence       | Product length (bp) |
| H-GAPDH Forward 5'- CATCATCTCCGTGCTCTACTG-3' | 259 |
| reverse 5'- GTGGGTTCTGCTTGAAGTC-3' |
| H-RORyt Forward 5'- TGGAACTGGTGCTGTTAGG-3' | 203 |
| reverse 5'- GAGAACAGGGCCTGTAGAGG-3' |
| H-RORytα Forward 5'- CCCTGAGGTGGTCGCGATT-3' | 211 |
| reverse 5'- TCAATGTAGTTACTGAGGTCGTCG-3' |
lymphocytic sialadenitis (Fig. 1a). We detected the expression of RORα in LSGs by different methods, and all indicated that RORα expression was significantly up-regulated in the LSGs of patients with pSS (Fig. 1b–d). RORα-expressing cells were observed in the LSGs of nearly all patients with sicca syndrome, even in those without obvious local lymphocytic sialadenitis (FS = 0) (Fig. 2b).

**RORA expression increased with increasing FS**

RORα expression was monitored in the LSGs of pSS patients with different FS and this indicated that RORα expression increased with increasing FS (Fig. 2c), which might suggest its participation in the pathogenesis of pSS. LSGs from all pSS patients with obvious focal lymphocytic accumulation (FS ≥ 1) had a high number of RORα-positive cells localized predominantly around the ducts (Fig. 2b, c). For RORα protein expression in LSG biopsy specimens intensified with disease stage/FS, there might be indicative of a correlation between RORα up-regulation and pathological manifestations in LSGs of pSS, but it remained unclear whether this deposition correlated with known markers of pSS, such as anti-Ro (SSA) and anti-La (SSB) antibodies, high erythrocyte sedimentation rate (ESR), or RF rheumatoid factor.

**The ratio of CD4+/IL-17A+ cells in the salivary gland was higher in patients with pSS than in control individuals**

RORα-positive Th17 cells were detected in LSGs from patients with pSS (Fig. 3), indicating that RORα regulates Th17 cell differentiation and is involved in the pathogenesis of pSS. IL-17 was secreted in large amounts by inflammatory cells from patients with pSS, which can facilitate pro-inflammatory responses and tissue destruction. An elevated number of IL-17-producing cells in patients with pSS was correlated with increased glandular inflammation, as indicated by an increased FS in the LSGs. A large number of IL-17-producing cells was observed in the vicinity of LSG lymphocytic infiltrates and in the interstitium.

**IL-17RA expression was significantly higher in salivary gland tissues from patients with pSS than in that from control individuals**

Immunohistochemical staining revealed substantial expression of IL-17RA in the LSGs from pSS patients (Fig. 4b), not only seen in infiltrated lymphocytes but also in acinus and ductal epithelial cells. Furthermore, high expression of IL-17RA was detected by western blot (Fig. 4a). In addition, IL-17RA expression also tended to increase with increasing disease stage/FS as did RORα. The number of IL-17+ cells may be inflated, because the widespread distribution of IL-17RA may confound quantification. It is not possible to dissociate cells that produce IL-17 from those that bind/respond to it, and multiple cell types may be responsible for secreting IL-17. Because of the difficulty in accurately quantifying IL-17RA-expressing populations by immunohistochemical analysis, we assessed IL-17RA by western blot of proteins extracted from whole LSGs from patients with pSS and control individuals (Fig. 4a). We observed higher IL-17RA expression in the LSGs of patients with pSS (n = 34) compared with control individuals (n = 12).

**Synthetic RORA inverse agonist improved salivary gland function and alleviated lymphocytic infiltration of salivary glands**

To verify the secretory function of salivary glands, saliva was collected from NOD mice. Significantly more saliva was collected from SR1001-treated NOD mice than from littermate vehicle controls in both the 4W and 8W groups (Fig. 5a), but the difference between the 8W groups was more significant (Fig. 5a). Then, NOD mice were sacrificed for histological analysis to determine the effect of SR1001 on sialadenitis development. More infiltrating mononuclear cells were detected in the SMGs of vehicle-treated NOD mice. SR1001 treatment significantly reduced lymphocytic infiltration of SMGs compared with littermate vehicle controls in both the 4W and 8W groups (Fig. 5b). This result might suggest that pharmacological inhibition of RORα effectively alleviated salivary gland destruction and improved salivary gland function.

Moreover, flow cytometry analysis of CD4+ T cells in MLNs and CLNs from different-aged NOD mice that received different treatments after stimulation with phorbol-12-myristate-13-acetate (PMA) and ionomycin for 6 h was performed to determine the effect of SR1001 on Th17 cell differentiation (Fig. 6). It indicated that SR1001, a synthetic RORα inverse agonist,
decreased Th17 differentiation of CD4+ T cells in MLNs and CLNs after 4-week treatment (Fig. 6). We also detected that SR1001 has the ability to regulate blood glucose in NOD mice, especially in mice at 8 weeks of age (Additional file 1B). Meanwhile, systemic treatment of SR1001 had no effect on body weight gain in NOD mice (Additional file 1A).

**Discussion**

Dry mouth, dry eyes and rampant caries due to a reduction in exocrine secretions are the main clinical manifestations of pSS, which cause patients considerable inconvenience and pain [18, 19]. As reported in previous studies, most patients with pSS are female [20, 21]. Lymphocytic infiltration of salivary glands and impaired saliva secretion are the main features of pSS. A variety of autoantibodies, such as high ESR, RF, and Ig, can be detected in the serum of patients with pSS. Although there have been great improvements in our knowledge and understanding of pSS, diagnosis, treatment and disease monitoring are still challenging in the clinic.

---

**Fig. 1** Higher RORα expression in the labial salivary glands (LSGs) of patients with primary Sjögren’s syndrome (pSS).  

**A** Pathological analysis of LSG sections. Left, histologic image of normal LSGs from non-SS patients (normal control (NC)). Right, typical histologic image of LSGs from patients with pSS, including acinus atrophy and local lymphocytic sialadenitis. Arrowheads indicate lymphocyte infiltration in connective tissue among glandular lobules and ducts. Scale bars = 200 μm.  

**B** Western blot showed that expression of RORα (68 KD) was significantly higher in whole LSGs of patients with pSS (n = 6) compared to NC (n = 4).  

**C** Gray-scale analysis. Data were normalized for glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Data are mean ± SEM. ***p < 0.001.  

**D** Expression of RORα (green) was higher in LSGs of patients with pSS shown by indirect immunofluorescence analysis. Nuclei stained by diamidino-phenyl-indole (DAPI) (blue). Scale bars = 100 μm.  

**E** Normalized fold difference in RORα expression between pSS (n = 34) and NC (n = 12) analyzed by densitometry. *p < 0.05.  

**F** Relative expression of RORα mRNA in whole LSGs of patients with pSS (n = 6) compared to NC (n = 4) are normalized for GAPDH mRNA and plotted as fold change over control. Data are mean ± SEM. ***p < 0.001.
**Fig. 2** RORα expression in the labial salivary glands (LSGs) of patients with primary Sjögren’s syndrome (pSS) increased with increasing focus score (FS). 

- **a** Focal index of all patients with pSS (n = 34) and the statistical analysis: 85.3% (n = 29) of pSS in our study had obvious local lymphocytic sialadenitis (FS ≥ 1).
- **b** Expression of RORα expression (green) in LSG sections from patients with pSS with a FS of 0 (n = 5, lower panel) was still higher than in patients without pSS (normal control (NC) (n = 10, upper panel) assessed by indirect immunofluorescence.
- **c** RORα expression in patients with pSS with a different FS (n = 29) assessed by indirect immunofluorescence analysis suggested that the RORα expression in the LSGs in pSS increased with increasing FS. Diamidino-phenyl-indole (DAPI) staining for nuclei (blue). Scale bars = 100 μm.

**Fig. 3** Co-expression of RORα with CD4 and IL-17A in the labial salivary glands (LSGs). Indirect immunofluorescence analysis was used to assess RORα (green), CD4 (green) and IL-17A (red) expression and diamidino-phenyl-indole (DAPI) staining for nuclei (blue) in the LSG. Results are representative of 30 patients with primary Sjögren’s syndrome (pSS) (lower lane) and 10 normal control individuals (NC) (upper lane). The micrographs in the lower panel showed RORα-positive T helper 17 (Th17) cells in the LSGs of patients with pSS (focus score (FS) = 2), whereas the upper panel only shows some RORα-positive cells in the LSGs of NC. It indicated RORα-positive Th17 cells in the periductal tissue of LSGs of patients with pSS. Serial sections of the LSG from the same patient, and yellow arrows (lower lane) in the same direction indicated the same cell in three serial sections. Scale bars = 100 μm.
pSS is known as an autoimmune disease caused by a group of different mechanisms, and immune disorder is important in pSS occurrence and development. Due to the complexity and integrity of the immune system, functional cells involved in immune responses may all be involved in the pathogenesis of pSS, in which the study of T/B cells predominates. The role of Th17 cells in autoimmune diseases has been widely recognized [14, 22]. In fact, lymphocytic infiltration into the exocrine glands of patients with pSS does not contain a single species but includes Th1, Th2, Th17, T regulatory (Treg), and B cells [23–25]. Treg cells are the most important immune-suppressing cells, and it is believed that the imbalance between Th17 cells and Treg cells is crucial in the progression of pSS [26, 27]. Th17 cells comprise a pro-inflammatory cell subset that can promote inflammatory reactions and secrete various pro-inflammatory factors [26]. Both patients with pSS and mouse models harbor Th17 cells and IL-17 in the salivary glands and in serum [28–30]. Furthermore, serum IL-17 levels are closely related to the degree of salivary gland damage [9].

Th17 cells and IL-17 do not directly lead to an inflammatory reaction. The pro-inflammatory effect is mainly due to pro-inflammatory cytokines, such as IL-6 and granulocyte-macrophage colony stimulating factor (GM-CSF), produced in response to IL-17 binding to IL-17RA, which occurs in the salivary glands and causes tissue damage [31, 32]. However, it has been proved that IL-17 was not essential for the development of sialadenitis by examination of IL-17-deficient mice [13]. The levels of IL-17A and IL-17RA can be regulated by each other [33, 34]; IL-17RA could be rapidly down-regulated by IL-17A binding [35], and IL-17RA has some ability to clear local IL-17A, which may reduce inflammation [36]. In the present study, we found Th17 cells and IL-17RA were significantly increased in the labial salivary glands (LSGs) of patients with primary Sjögren’s syndrome (pSS), a Protein expression level of IL-17R (96 kD) in LSGs. Expression of IL-17R in tissue with pSS (n = 6) was higher compared with normal control (NC) (n = 4). b Immunohistochemical analysis of local IL-17R in patients with pSS (n = 34) and NC (n = 10) LSGs. IL-17R-positive cells are significantly more numerous in the LSGs of patients with pSS compared with NC, along with an upward trend as the focus score (FS) increased. Scale bars = 50 μm; insets, × 2 magnification. Abbreviations: A, acinus; Adip, adipocytes; Bv, blood vessel; D, ductus; Ly, lymphocyte infiltration.
cells [11, 14, 18]. In this study, we found that RORα expression was significantly higher in the LSGs of patients with pSS than in non-SS LSGs, and it showed a trend of increasing as FS increased. These data suggested that RORα expression is associated with the progression of pSS. These results may be attributed to the effects of RORα on Th17 cells, i.e., increased IL-17 synthesis and secretion, because RORα-positive Th17 cells were detected in the salivary glands of patients with pSS in our study. Approximately 25% of patients diagnosed as having pSS had no obvious evidence of sialadenitis in LSG biopsies, which is consistent with the results of previous studies [3]. Nevertheless, the LSGs in patients with pSS without obvious FS still had extensive, high RORα expression in the interstitial tissue and epithelial cells compared with LSGs in normal controls. RORα detection may distinguish patients with and without pSS among patients with suspected pSS. However, it is necessary to define the criterion for quantifying RORα. Moreover, it is unknown whether there is a relationship between RORα and disease severity, as there is for the proportion of Th17 cells and IL-17 levels in peripheral blood lymphocytes from patients with pSS, and whether these diagnostic criteria are true in the salivary glands. If these criteria are also established in serum, it will be possible to diagnose pSS without performing an invasive lip biopsy. Since the sample size was small, the conclusion must be confirmed by further clinical case reports and experimental studies.

RORα can bind to certain small molecule ligands, such as cholesterol and oxysterols, to exert biological effects [41–43]. Recently, some synthetic RORα-specific inverse agonists have been reported and shown to be effective in controlling autoimmune diseases associated with Th17 cells in animal experiments [11, 44–48]. SR1001 is a highly selective and specific RORα/yt inverse agonist that specifically binds to RORα/yt and inhibits the differentiation of Th17 cells [44]. In our study, we investigated the effect of SR1001 in the treatment of pSS and found that SR1001 could significantly improve salivary gland function and alleviate lymphocyte infiltration into the submandibular glands; however, this effect was not obvious in the sublingual glands, since the submandibular glands in NOD mice are most likely to exhibit spontaneous sialadenitis [49]. Flow cytometry analysis showed
that SR1001 could inhibit the differentiation of Th17 cells without affecting overall mouse development. In addition, SR1001 significantly controlled the progression of type I diabetes mellitus and had no obvious side effects on mouse development (Additional file 1). Older NOD mice had a greater improvement in salivary gland function after SR1001 treatment, so we speculated that it is possible that RORα has a different effect at different stages of pSS. At the early stage of pSS, RORα does not have a major effect because it has lower expression or activity, while at the progressive stage, it is prominent because of higher expression or activity. Although we showed that SR1001 can alleviate inflammation and improve salivary gland function, with better results in older NOD mice, additional studies are necessary to confirm this result.

Since SR1001 not only inhibits RORα, but also inhibits RORγt [44, 48], it was uncertain whether these effects stemmed from the inhibition of RORα and/or RORγt. We also detected the expression of RORγt to determine which is dominant in the process of inflammation of the LSGs. The results showed that the expression of RORγt in the LSGs in patients with pSS was markedly higher than that in patients without pSS (Additional file 2A, B). RORγt-positive cells were seen in infiltrated lymphocytic cells and also in some acinar cells and ductal cells on immunohistochemical staining (Additional file 2C). However, we realized that the expression of RORγt displayed no obvious increasing tendency with progressive disease stage/FS, and RORγt overexpression was even more evident in scattered lymphocytes from the LSGs of patients with pSS, who had a lower histological score for inflammatory lesions. This was different from what we found about RORα in the present study. Based on this finding, we speculated that acinar cells or salivary gland duct cells themselves could have RORγt overexpression in pSS. It has been reported that RORγt overexpression induced severe spontaneous sialadenitis-like SS via RORγt overexpressed CD4+ cells and reduced Treg [13]. We hypothesized that this expression of RORγt by acinar cells or salivary gland duct cells may not be important in the differentiation of Th17 cells in patients with pSS. In addition, we did not find other data on representing relation between RORγt and pSS progression as what we found on RORα. Though several
autoantigens have been identified in pSS, none of them are only pSS-specific. Data from our study might provide support to the notion that RORα may be an index sign of accersory diagnosis and classification for pSS. Nevertheless, RORα affects a wide range of biological processes, such as biological rhythms, so further studies are needed to validate potential underlying mechanisms of how RORα is involved in the progression of salivary gland inflammation in patients with pSS.

Conclusion
In summary, this is the first study of different RORα expression between patients with pSS and normal controls through the effect on Th17 cells. In patients with pSS, RORα expression increased with increasing FS, and there was positive correlation between these two factors. Specific inhibition of RORα inhibited the differentiation of Th17 cells, relieved salivary gland inflammation and improved salivary gland function. Our study may offer a new prospect for the diagnosis, classification, and treatment of pSS.

Additional file

Additional file 1: The effects of SR1001 on blood glucose level and weight gain in NOD mice. A Body weight gain in NOD mice treated with SR1001 or vehicle for 4 weeks. There were no significant differences among these groups. Data represent means ± SEM (n = 5 for each group), p > 0.05. B SR1001 ameliorated the blood glucose level in NOD mice at 8 weeks of age (**p < 0.001), whereas there was no obvious effect on 4-week-old mice (p > 0.05). Data represent means ± SEM (n = 5 for each group). (JPG 453 kb)

Additional file 2: RORγt expression in LSGs. A Western blot showed that expression of RORγt (56 kD) was also significantly higher in whole LSGs from patients with pSS (n = 6) compared to non-pSS (n = 4). B Gray scale analysis. Data were normalized for GAPDH. Result represent the mean ± SEM. ***p < 0.001. C Relative expression of RORγt messenger RNA (RNA) in whole LSGs from patients with pSS (n = 6) was significantly more abundant compared to normal controls (NC, n = 4) normalized for GAPDH mRNA. The mean ± SEM is shown. ***p < 0.001. D Immunohistochemical analysis of RORγt in pSS (n = 34) and normal (n = 10) LSGs. RORγt-positive cells are more numerous in LSGs of patients with pSS compared with normal FS compared with normal controls. Scale bars = 50 μm; insets, ×2 magnification. (JPG 1351 kb)

Abbreviations
ANA: Anti-nuclear antibody; BSA: Bovine serum albumin; C3: Component 3; C4: Component 4; CLNs: Cervical lymph nodes; DAPI: Diamidino-phenyl-indole; DMSO: Dimethyl Sulphoxide; ECL: Enhanced chemiluminescence; ESR: Erythrocyte sedimentation rate; FS: Focus score; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; GM-CSF: Granulocyte-macrophage colony stimulating factor; H&E: Hematoxylin and eosin; IgG: Immunoglobulin G; IL-17RA: Interleukin-17 receptor A; IκB: Nuclear factor κB inhibitor C; LSG: Labial salivary gland; MLNs: Mesenteric lymph nodes; MSG: Minor salivary gland; NC: Normal controls; NOD: Non-obese diabetic; PBS: Phosphate-buffered saline; PCR: Polymerase chain reaction; PrM: Prorobil-12-myristate-13-acetate; pSS: Primary Sjögren’s syndrome; RF: Rheumatoid factor; RIPA: Radio-immunoprecipitation assay; RORα: Orphan nuclear receptors retinoic acid-related receptor α; RORγt: Orphan nuclear receptors retinoic acid-related receptor γt; SLG: Sublingual gland; SMG: Submandibular gland; SS: Sjögren’s syndrome; SSA: Anti-Sjögren’s-syndrome-related antigen antibody A; SSB: Anti-Sjögren’s-syndrome-related antigen antibody B; TBST: Tris-buffered-saline Tween; TH17: T helper 17; Treg: Regulatory T

Acknowledgements
We would like to thank Cong-yl Wang, Shu Zhang, and Sunchang Zhou for technical assistance, You Song for valuable discussion on the pSS study and the department of pathology of Union hospital, Wuhan for the histologic analysis of LSG sections.

Funding
The present work was supported by grants from National Natural Science Foundation of China (number 81370405).

Authors’ contributions
All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. XHW carried out sample handling and collection of information, the isolation of protein and RNA, western blot, immunofluorescence, immunohistochemical analysis, animal research design and the SR1001 intervention, and the flow cytometry. YL coordinated the sample collection, isolation of protein and RNA, western-blot and real-time PCR. BC conceived and designed the study, performed data analysis, drafted the manuscript, and finalized the manuscript. SC participated in the study design, data analysis, and manuscript revision.

Ethics approval and consent to participate
Collection of LSG specimens was conducted with the approval of the Ethics Committee of Tongji Medical College, Huazhong University of Science and Technology and the subjects gave informed consent. All animal experiments were conducted with the approval of the animal Ethics Committee of Huazhong University of Science and Technology. The Ethics Committee of Tongji Medical College, Huazhong University of Science and Technology (IORG number IORG0003571) gave final approval on 10/05/2015 for the study The Role of RORα in Salivary Gland Lesions in Patients with Primary Sjögren’s Syndrome, which is conducted by Cheng Bo at the Department of Stomatology, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology. This Ethics Committee is constituted and functioned in accordance with ICH-GCP, GCP in China and the Declaration of Helsinki (2013).

Consent for publication
All authors have read and approved the manuscript for publication.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Stomatology, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuhan 430071, Hubei Province, China. 2Department of Stomatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Ave, Jianhan District, Wuhan 430022, Hubei Province, China. 3Department of Rheumatology, Union Hospital, Tongji Medical College, Wuhan University of Science and Technology, 1277 Jiefang Ave, Jianghan District, Wuhan 430022, Hubei Province, China.

Received: 9 August 2017 Accepted: 7 August 2018

Published online: 06 September 2018

References
1. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med. 2005;165(20):2337–44.
2. Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR, Costa J, Decker JL, Chused TM. Increased risk of lymphoma in sicca syndrome. Ann Intern Med. 1978;89(6):888–92.
3. Yazisiz V, Avci AB, Erbasan F, Kiris E, Terzioglu E. Diagnostic performance of minor salivary gland biopsy, serological and clinical data in Sjögren’s syndrome: a retrospective analysis. Rheumatol Int. 2009;29(4):403–9.
4. Teppo H, Revonta M. A follow-up study of minimally invasive lip biopsy in the diagnosis of Sjögren’s syndrome. Clin Rheumatol. 2007;26(7):1099–103.
5. Vitali C. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European consensus group. Ann Rheum Dis. 2002;61(6):554–8.

6. Moriyama M, Hayashida JN, Toyoshima T, Ohyama Y, Shinohzaki S, Tanaka A, Maehara T, Nakamura S. Cytokine/chemokine profiles contribute to understanding the pathogenesis and diagnosis of primary Sjogren's syndrome. Clin Exp Immunol. 2012;169(1):17–26.

7. Lin X, Rui K, Deng J, Tian J, Wang X, Wang S, Ko KH, Jiao Z, Chan VS, Lau CS, et al. Th17 cells play a critical role in the development of experimental Sjogren's syndrome. Ann Rheum Dis. 2015;74(6):1302–10.

8. Ciccia F, Guggino G, Rizzo A, Ferrante A, Raimondo S, Giardina A, Dieli F, Campisi G, Alessandro R, Triolo G. Potential involvement of IL-22 and IL-22-producing cells in the inflamed salivary glands of patients with Sjogren's syndrome. Ann Rheum Dis. 2012;71(2):295–301.

9. Nguyen CC, Hu MH, Li Y, Stewart C, Peck AB. Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sjogren's syndrome: findings in humans and mice. Arthritis Rheum. 2008;58(3):743–4.

10. Wu C, Wang Z, Zucarello L, Thakker H, Basnet M, Zhao L, Zourelias L, Thakker H, Passineau MJ. IL-17 sequestration via the putative autocrine Kikl1b22. Arthritis Res Ther. 2017;15:198.

11. Kojetin DJ, Burns TP. REV-ERB and ROR nuclear receptors as drug targets. Nat Rev Drug Discov. 2014;13(3):197–216.

12. Ruan Q, Kameswaran V, Zhang Y, Zheng S, Sun J, Wang J, DeVellis J, Liou HC, Beg AA, Chen YH. The Th17 immune response is controlled by the Rel-RORgamma-RORgamma T transcriptional axis. J Exp Med. 2010;208(1):2321–33.

13. Iizuka M, Tsuboi H, Matsuo N, Asashima H, Hirota T, Kondo Y, Iwakura Y, Takahashi S, Matsui T, Sumida A. T cell mediated autoimmunity in mice lacking ROR-γt. Hum Immunol. 2015;76(3):349–55.

14. Cohen RD, Devauchelle-Pensec V, Tobon GJ, Pers JO, Jousse-Joulin S, Saraux A, B cell therapy for Sjogren's syndrome: from pathophysiology to diagnosis and treatment. J Autoimmun. 2012;39(3):161–7.

15. Littman DR, Kroese FG, Vissink A, Bootsma H. Immune regulation and B-cell depletion therapy in patients with primary Sjogren's syndrome. J Autoimmun. 2012;39(1):102–3.

16. Bouloumgour A, Devauchelle-Pensec V, Tobon GJ, Pers JO, Jousse-Joulin S, Saraux A. B cells in Sjogren's syndrome: from pathophysiology to diagnosis and treatment. J Autoimmun. 2012;39(3):161–7.

17. Littman DR, Kroese FG, Vissink A, Bootsma H. Immune regulation and B-cell depletion therapy in patients with primary Sjogren's syndrome. J Autoimmun. 2012;39(1):102–3.

18. Cornec D, Devauchelle-Pensec V, Tobon GJ, Pers JO, Jousse-Joulin S, Saraux A, B cells in Sjogren's syndrome: from pathophysiology to diagnosis and treatment. J Autoimmun. 2012;39(3):161–7.

19. Alamanos Y, Tsifetaki N, Voulgari PV, Venetsanopoulou MA, Siozos C, Drosos AA. Epidemiology of primary Sjogren's syndrome in north-west Greece, 1982-2003. Rheumatology (Oxford). 2006;45(2):187–91.

20. Bouma VK, Vlachoianopoulos PG. Subgroups of Sjogren syndrome patients according to serological profiles. J Autoimmun. 2012;39(1):1–25.

21. Xu J, Racte MK, Drew PD. Peroxisome proliferator-activated receptor-alpha agonist fenofibrate regulates IL-12 family cytokine expression in the CNS: relevance to multiple sclerosis. J Neurochem. 2007;105(3):1801–10.

22. Bikker A, Moret FM, Kruize AA, Blijma JW, Lefebre FP, van Roon JA, IL-7 drives Th1 and Th17 cytokine production in patients with primary SS despite an increase in CD4 T cells lacking the IL-7Ra. Rheumatology (Oxford). 2012;51(6):996–1005.

23. Abdulahad WH, Kroese FG, Vissink A, Bootsma H. Immune regulation and B-cell depletion therapy in patients with primary Sjogren's syndrome. J Autoimmun. 2012;39(1):102–3.

24. Cornec D, Devauchelle-Pensec V, Tobon GJ, Pers JO, Jousse-Joulin S, Saraux A, B cells in Sjogren's syndrome: from pathophysiology to diagnosis and treatment. J Autoimmun. 2012;39(3):161–7.

25. Littman DR, Kroese FG, Vissink A, Bootsma H. Immune regulation and B-cell depletion therapy in patients with primary Sjogren's syndrome. J Autoimmun. 2012;39(1):102–3.
47. Kumar N, Solt LA, Conkright JJ, Wang Y, Istrate MA, Busby SA, Garcia-Ordóñez RD, Burris TP, Griffin PR. The benzenesulfoamide T0901317 ([N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-benzenesulfonamide] is a novel retinoic acid receptor-related orphan receptor-alpha/gamma inverse agonist. Mol Pharmacol. 2010;77(2):228–36.

48. Solt LA, Banerjee S, Campbell S, Kamenecka TM, Burris TP. ROR inverse agonist suppresses insulitis and prevents hyperglycemia in a mouse model of type 1 diabetes. Endocrinology. 2015;156(3):869–81.

49. Lavoie TN, Lee BH, Nguyen CQ. Current concepts: mouse models of Sjogren’s syndrome. J Biomed Biotechnol. 2011;2011:549107.